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Analgesia is a well-documented eﬀect of acupuncture. A critical role in pain sensation plays the nervous system, including the
GABAergic system and opioid receptor (OR) activation. Here we investigated regulation of GABA transporter GAT1 by δOR in
rats and in Xenopus oocytes. Synaptosomes of brain from rats chronically exposed to opiates exhibited reduced GABA uptake,
indicating that GABA transport might be regulated by opioid receptors. For further investigation we have expressed GAT1 of
mouse brain together with mouse δOR and μOR in Xenopus oocytes. The function of GAT1 was analyzed in terms of Na+-
dependent [3H]GABA uptake as well as GAT1-mediated currents. Coexpression of δOR led to reduced number of fully functional
GAT1 transporters, reduced substrate translocation, and GAT1-mediated current. Activation of δOR further reduced the rate of
GABA uptake as well as GAT1-mediated current. Coexpression of μOR, as well as μOR activation, aﬀected neither the number of
transporters, nor rate of GABA uptake, nor GAT1-mediated current. Inhibition of GAT1-mediated current by activation of δOR
was conﬁrmed in whole-cell patch-clamp experiments on rat brain slices of periaqueductal gray. We conclude that inhibition of
GAT1 function will strengthen the inhibitory action of the GABAergic system and hence may contribute to acupuncture-induced
analgesia.
1.Introduction
Neurotransmitter transporters play a key role in the regu-
lation of synaptic transmission. Glutamate and GABA are
the dominating excitatory and inhibitory neurotransmitters
in the mammalian brain, respectively. The predominate
transporters controlling glutamate and GABA in the CNS
are the excitatory neurotransmitter transporter EAAC1 [1–
3] and the GABA transporter GAT1 [4].
It is generally accepted that pain sensation can be
suppressed by acupuncture and that regulation of the glu-
tamatergic and the GABAergic systems is involved in
pain sensation [5]. Inhibition of the excitatory glutamater-
gic system and stimulation of the inhibitory system will
contribute to analgesia. It could be demonstrated that
inhibition of excitatory amino acid (EA) receptors [6, 7]
and stimulation of GABA-A and GABA-B receptor [5, 8]
resulted in pain suppression. Indirect reduction of EA-
receptor activity may also be achieved by reduced gluta-
mate concentration in the synaptic cleft, and reduction
of glutamate concentration can be achieved by stimulat-
ing EAAC activity [9, 10]. In analogy to stimulation of
EAAC1, we may expect for the GABAergic system that
inhibition of the GABA transporter will result in elevation2 Evidence-Based Complementary and Alternative Medicine
of GABA concentration in the synaptic cleft and hence in
stimulation of GABA receptor activity; this could contribute
to increased inhibitory synaptic transmission and also to
reduced pain sensation. Indeed, experiments with transgenic
mice with knockout or overexpressed GABA transporters
GAT1 have demonstrated that the GAT1 is correspondingly
involved in pain sensation [11]. In these experiments it
could also be shown that application of GAT1-selective
inhibitors, ethyl nipecotate and NO-711, led to analgesia.
Though GAT1 is the dominating neuronal GABA trans-
porter, involvement of nonneuronal transporters cannot be
excluded.
GAT1 belongs to a family of secondary active systems
(see [12]) that are driven by electrochemica1 gradients
for Na+ and Cl−. The transport of one GABA is coupled
to the cotransport of two Na+ and one Cl− [13–18].
As a consequence of the stoichiometry, the translocation
of GABA across the cell membrane is associated with a
current that can be measured under voltage clamp. In the
absence of GABA, the transport cycle is not completed,
but transient charge movements can be detected; they
reﬂect extracellular Na+ binding within the electrical ﬁeld
preceding binding of GABA [19–22]. The GAT1-mediated
steady-state current, on the other hand, often reﬂects only
in part the translocation of GABA; another component
of GAT1-mediated current represents uncoupled ﬂow of
ions through a channel-like mode (see, e.g., [15, 18,
23]).
It was shown previously [24] that acupuncture leads
to activation of enkephalinergic neurons and release of
endogenous morphines, the endorphins. Activation of opi-
oid receptors has also been shown to regulate pain sensation,
and the role of δOR in pain modulation is intriguing [25,
26], Importantly, δOR has been found to be increasingly
targeted to the plasma membrane in the spinal cord dorsal
horn in inﬂammation [27]. Loss of synaptic inhibition
including GABAergic inhibition in the spinal dorsal horn
is considered to contribute signiﬁcantly to several forms
of chronic pain [8, 28], and regulation of GABA trans-
portation has been shown to control pain sensation [11,
29]. Since control and termination of synaptic activity
play important roles in physiological and pathophysiolog-
ical brain functions, regulation of the GABA transporter,
which controls the dominating inhibitory transmitter in
extracellular space, is a crucial mechanism to regulate neural
circuits.
In the present study, potential eﬀects of opiates on GABA
transporter were examined, and we found that chronic
exposure of rats to morphine reduced GABA uptake into
synaptosomes. We have previously shown [9] that the gluta-
matetransporterEAAC1isdownregulatedbyintermolecular
interaction with the Gi-protein-coupled δ-opioid receptor
of mouse (δOR) [30] and that this inhibitory interaction
is counteracted by activation of the δOR [9]. In the work
described here, we present evidence that the δOR interferes
with functional surface expression of the GABA transporter
GAT1 and that δOR activation results in reduced activity of
the GAT1.
2.MaterialsandMethods
2.1.Experimentson Animals andSynaptosomes. For studying
eﬀects of opiates in animal experiments, male Sprague-
Dawley rats (200–220g, Laboratory Animal Center, Chinese
Academy of Sciences, Shanghai, China) were used. All
experiments were carried out strictly in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
Rats were exposed to opioids by s.c. injection of mor-
phine (10mg/kg) twice per day at 12h intervals for a period
of 10 days as described recently [31, 32]. Control rats were
treated similarly, except saline was used throughout. After
decapitation of rats, the brains were removed and cooled
brieﬂy in chilled balanced salt solution (in mM): 126 NaCl,
5 KCl, 1.25 NaH2PO4,1 0g l u c o s e ,2 5N a H C O 3,2C a C l 2,
and2MgSO4,(pH7.4).Thereafter,hippocampiwererapidly
dissected. Hippocampi express both GAT1 [33]a n dδOR
in GABAergic cells [34]. Subcellular fractions were prepared
according to standard methods as described previously [35].
The puriﬁed synaptosomes were from P2 fraction of the
brain lysate [36].
GABA uptake of synaptosomes was initiated by adding
4nM[ 3H]-GABA (Amersham Pharmacia Biotech, Bucking-
hamshire, UK) and 30μM unlabeled GABA in a ﬁnal volume
of 500μL KRH (Krebs Ringer’s/HEPES) medium [37]. After
incubation at 37◦C for 5min, the uptake was terminated by
ﬁltration on a GF/C ﬁlter (Whatman) under vacuum, and
the ﬁlter was washed ﬁve times with 10mL of cold KRH
medium. Finally, ﬁlters containing synaptosomal particles
or neuronal lysates were processed for scintillation counting
(Beckman Instruments, Torrance, CA). Nonspeciﬁc uptake
was determined using Na+-free media to block GABA
transport.
2.2. Experiments on Oocytes. Xenopus oocytes were obtained
as described previously (see, e.g., [38]). Full-grown pro-
phase-arrested oocytes were injected with cRNA for GAT1
or/and δOR of mouse brain or μOR of rat brain, or for
the rat α2β Na+,K + pump. cDNA for GAT1 was kindly
provided by Dr. Jian Fei (Shanghai, Tongji University). The
cells together with noninjected control oocytes were stored
at 19◦C in oocyte Ringer’s solution (ORi (in mM): 90
NaCl, 2 KCl, 2 CaCl2, 5 MOPS (adjusted to pH 7.4 with
Tris)) containing 70mg/L gentamicin. The agonist of δOR,
[d-Pen2,5]-enkephalin (DPDPE), the agonist [d-Ala2,N-Me-
Phe4,Gly5-ol]-enkephalin (DAMGO) of μOR, and the gen-
eralopioidreceptorantagonistnaloxone(Sigma)wereadded
at the respective concentrations to ORi. Experiments were
performed at room temperature (about 22◦C) after 3–5 days
of incubation.
Membrane currents were recorded under conventional
two-electrode voltage clamp (TurboTec, NPI, Tamm, Ger-
many) during rectangular 200ms voltage-clamp pulses
(from −150 to +30mV in 10mV increments that were
applied from a holding potential of −60mV (see, e.g., [39]).
Voltage dependencies of steady-state and transient mem-
brane currents were analyzed [21]. Steady-state current was
determined at the end of the voltage pulses (averaged duringEvidence-Based Complementary and Alternative Medicine 3
thelast20ms),andtransientcurrentswereanalyzedfromthe
entire time course during the respective voltage step.
GAT1-mediated currents were calculated as the diﬀer-
ence of current in the presence and absence of GABA.
Current values determined before and after the application
of GABA were averaged to correct for small drifts with time.
Todeterminemaximumtransportactivity,uptakeof 3H-
labeled GABA (Amersham, Braunschweig, Germany) was
measured at 90mM external Na+ as describe previously
[21] using a total concentration of 100μM GABA. The
number of Na+,K + pump molecules in the oocyte surface
membrane was determined by [3H]-ouabain binding; the
oocytes were preloaded with Na+ by incubating the cells
for 40min in solution that had the following composition
(in mM): 110 NaCl, 2.5 sodium citrate, and 5 MOPS
(adjusted to pH 7.6). In the loaded oocytes, intracellular
activity of Na+ was about 80mM after 40min of incubation
as measured by Na+-selective microelectrodes [40]. The
number of ouabain binding sites on the oocyte surface
w a sd e t e r m i n e di nK +-free ORi solution containing 2.5μM
[3H]ouabain (0.86TBq/mmol, New England Nuclear) and
2.5μMo fc o l do u a b a i na tr o o mt e m p e r a t u r e[ 38].
2.3. Experiments on Brain Slices. Neonatal Sprague-Dawley
rats (10–20 days) were anaesthetized with ether, decapitated
andhorizontalmidbrainslicescontainingtheperiaqueductal
gray (PAG) were cut (350μm) in ice-cold (4◦C) artiﬁcial
cerebrospinalﬂuid(ACSF),andthecompositionoftheACSF
was in mM as follows: NaCl 124, KCl 3.0, NaH2PO4 1.25,
MgSO4·7H2O 2.5, NaHCO3 26, glucose-H2O 10, and CaCl2
2.0. For recovery the slices were kept at room temperature
(25◦C) in ACSF equilibrated with 95% O2 and 5% CO2 for
∼1 hour. The slices were then individually transferred to a
chamber and superfused continuously with ACSF (31◦C) for
electrophysiological experiments.
PAG neurons were visualized using infrared Nomarski
optics. Whole-cell recordings were made using patch elec-
trodes (4-5MΩ); the composition of the electrode ﬁlling
solution was (in mM) as follows: K-gluconate 95, KCl 30,
NaCl 15, MgCl2 2, HEPES 10, EGTA 11, MgATP 2, and
NaGTP 0.25 (pH 7.3, 280–285mOsmol/L). Liquid junc-
tion potentials of ∼30mV were corrected. Series resistance
(∼35MΩ)wascompensatedautomaticallyandcontinuously
monitored. Whole-cell currents were recorded using EPC10
double ampliﬁer (HEKA Instruments), digitized, ﬁltered
(at 2kHz), and then acquired (sampling at 10kHz) in
PatchMaster (HEKA Instruments). Steady-state currents
were determined at the end of 200ms, rectangular voltage-
clamp pulses (from −130 to −30mV in 10mV increments,
averaged during the last 20ms) that were applied from
a holding potential of −60mV. GAT1-mediated current
was determined as the current component that was inhib-
ited by either 20μM tiagabine (Biotrend Chemicals AG,
Zurich, Switzerland) or 10μM NNC711 (Tocris Cookson
Ltd, Bristol, UK). To reduce background contribution of
voltage-gated Na+,C a 2+,a n dK + channels, all bath solutions
contained 300nM tetrodotoxin, 10μM CdCl2,a n d2 0 m M
tetraethyl ammonium chloride, respectively.
2.4. Western Blot. Yolk-free homogenates of oocytes were
prepared 3 days after the injection of cRNA as described
previously [41] and by passing the oocytes through 200-μL
Eppendorf pipette tips in homogenization buﬀer (in mM:
20 Tris-HCl (pH 7.4), 5 MgCl2,5N a H 2PO4, 1 EDTA, 100
NaCl, 10 KCl, 1 DTT, and 1 PMSF, and 5μg/mL of each
of leupeptin, pepstatin, and antipain). Twenty-microliter
aliquots of the yolk-free homogenates were electrophoresed
on SDS-PAGE. Proteins from nonstained gels were elec-
trophoretically transferred on nitrocellulose membrane for
western blot. The primary antibody against GAT1 from
rabbit (Chemicon Int. AB1570 W) was applied overnight
at 4◦C. The secondary antibody against GAT1 from rabbit
(abcam. ab426) was applied at room temperature for 1hr.
Band intensities were quantiﬁed using ImageJ software.
3. Results
3.1. Exposure of Rats to Morphine Results in Reduced Rate
of GABA Uptake. Rate of GABA uptake was determined
in synaptosomal preparations of hippocampus of rats that
were chronically treated with morphine (Figure 1). Ratswere
injected twice a day with morphine over a period of 10 days,
and GABA uptake into the synaptosomes was signiﬁcantly
reduced 12h after termination of the morphine treatment
comparedtountreatedcontrols.Acuteinjectionofmorphine
(1h before sacriﬁce) further decreased the uptake activity.
This additional eﬀect of morphine could completely be
prevented by the simultaneous use of naloxone, an opioid
receptor antagonist, indicating that the acute morphine
treatment downregulated GABA transporter activity as a
result of activation of opioid receptors.
Among the several canonical opioid receptors, μOR
has the highest aﬃnity with morphine [42]; studies with
μOR knockout mice also show that μOR is necessary
for morphine-induced analgesia and other symptoms [43].
However, at a relatively high concentration, morphine could
bind to all three opioid receptors, μOR, δOR, and κOR
[44]. In addition, a minor morphine metabolite, morphine-
6-glucuronide, showed higher aﬃnity to δOR and lower
aﬃnity to μOR, compared to that of morphine in rodents
and human [42].
While μOR is constitutively expressed at surface mem-
brane, several studies have shown that the surface expression
of δOR is regulated by inﬂammation, drug exposure, or
stimulation [27, 45, 46]. Notably, the physical interactions
between μOR and δOR may contribute to long-term changes
of morphine-induced analgesia [44, 45]. We reasoned that
the changes of either μOR or δOR signaling cascades might
be responsible for acute and chronic morphine-induced
GABA uptake inhibition. Therefore, we next examined the
interaction between GAT1 and μOR or δOR using oocyte as
a simpliﬁed and well-controlled system.
3.2. Eﬀect of Opioid Receptor Coexpression on Rate of
GABA Uptake. To investigate regulation of GAT1 by opioid
receptor, we used the Xenopus oocytes with heterologously
expressed GAT1 and opioid receptor as a model system.4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Eﬀect of chronic morphine treatment on GABA uptake
activity in rats. Uptake activity was measured in synaptosomes of
untreated rats (control) and of rats after 10 days of morphine
injection twice a day (hatched bars). Data were normalized to the
rate of uptake into synaptosomes of controls. For treated rats, rate
of GABA uptake was determined 12hr after the termination of
treatment (morphine), with an additional injection of morphine
(s.c. 10mg/kg) 1hr before sacriﬁcing (morphine + morphine)
or with an additional injection of both morphine and naloxone
(i.p. 2mg/kg) 1hr before sacriﬁcing (morphine + morphine +
naloxone). ∗P<0.05, ∗∗P<0.01 compared to data from control
animals; n = 5i ne a c hg r o u p .E r r o rb a r sr e p r e s e n tS E M .
FunctionalGABAtransportersincorporationintotheoocyte
membrane was veriﬁed by detection of Na+-dependent
uptake of [3H]GABA at a saturating GABA concentration
of 100μM[ 14, 19]. Only oocytes with heterologously
expressed GAT1 showed signiﬁcant [3H]GABA uptake (see
Figure 3(a)). When GAT1 and the δOR of mouse brain
were coexpressed in Xenopus oocytes by coinjection of cRNA
for GAT1 (40ng) and diﬀerent amounts for δOR (0, 5,
10, 20, 40ng), increasing amounts of the coinjected cRNA
of δOR led to decreased rate of GAT1-mediated GABA
uptake (Figure 2); the dependency was arbitrarily ﬁtted
by
Rate =
Kn
1/2
Kn
1/2 +[cRNAδOR]
n (1)
with half-maximum inhibition of the rate at K1/2 = 10.7ng
and n = 1.7. Corresponding amounts of cRNA for the
rat Na pump, rα2β, had no signiﬁcant eﬀect on the GAT1-
mediated uptake (Figure 2). To rule out the possibility that
expression of δOR in the oocytes may aﬀect translation of
other proteins that regulate membrane protein expression,
we injected oocytes diﬀerent amounts of cRNA for δOR
together with cRNA for the rat α2β Na+ pump (40ng).
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Figure 2: Dependence of GAT1-mediated rate of [3H]GABA
uptake on diﬀerent amounts of coinjected cRNA. For cRNA of
δOR (ﬁlled squares) or rα2β pumps (ﬁlled circles), the amount of
injected cRNA for GAT1 was 40ng. Data were normalized for each
batch of oocytes to the respective value obtained from oocytes not
coinjected with cRNA for δOR or rα2β and are presented as means
±SEMfrom2to3batchesofoocytes(with8–10oocytesperbatch).
T h ed e p e n d e n c eo fr a t eo fG A B Au p t a k eo nδOR-cRNA was ﬁtted
by (1).
The coexpression of δOR did not aﬀect surface expression
of the pump as judged by [3H]ouabain binding (not illus-
trated). For the experiments described in the following, we
always choose 10 or 20ng for coinjection of opioid-receptor
cRNA.
The reduced uptake in oocytes expressing both the
GAT1 and the δOR compared to those expressing GAT1
alone cannot be attributed to background activation of
δOR since treatment with the opioid receptor antagonist
naloxone (1μM) could only slightly reverse the inhibition
(Figure 3(a)).Coinjectionof10ngcRNAfortheμORinstead
of cRNA for δOR had no signiﬁcant eﬀect on the rate of
GABA uptake (Figure 3(b)). Functional expression of δOR
and μOR was conﬁrmed in the absence of GAT1 activity
by application of 100nM of the δOR or μOR agonists,
DPDPE or DAMGO, respectively, and by the resulting
activation of the endogenous Ca2+-activated channels (data
not shown, see also [30]); it is worth to mention that the
voltage dependencies of the currents induced by DPDPE
and DAMGO diﬀer from each other indicating that diﬀerent
signaling pathways are activated.
We further tested the eﬀects of the opioid agonists if
10ng of cRNA for the respective receptor was coinjected.
Figure 3(b) shows that activation of δOR by 100nM DPDPE
further reduced the rate of GABA uptake while activation
of μOR by 100nM DAMGO did not signiﬁcantly change
transportactivity.SincetheheterologousexpressionofGAT1
withδOR,butnotμOR,exhibitedsigniﬁcanteﬀectonGABA
uptake, we focused the rest of our study on δOR.Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀect of opioid receptor coexpression on GAT1-mediated rate of GABA uptake. (a) 40ng of GAT1 cRNA alone or 40ng of GAT1
and 20ng of cRNA for δOR were injected into oocytes. Application of 100nM naloxone gave slight recovery of GAT1 inhibition by the
coexpressed δOR. (b) 40ng of GAT1 cRNA alone or 40ng of GAT1 and 10ng of cRNA for δOR or μOR were injected into oocytes. The
unspeciﬁc rate of uptake was subtracted from the uptake rate of injected oocytes. δOR was activated by application of 100nM DPDPE, μOR
by100nMDAMGO.DatawerenormalizedforeachbatchofoocytestotherespectivevalueobtainedfromoocytesnotcoinjectedwithcRNA
for δOR and are presented as means of rates of [3H]GABA uptake ± SEM from 2 to 4 batches of oocytes (with 5–10 oocytes per batch),
∗P<0.05.
3.3. Eﬀect of Opioid Receptor Coexpression on GAT1-Mediated
Steady-State Current. Dependence of GAT1-mediated cur-
rent on membrane potential was determined in voltage-
clamp experiments as the diﬀerence of membrane current in
the presence and the absence of 100μM GABA. Figure 4(a)
shows original current traces before, during, and after appli-
cation of GABA. The steady-state GAT1-mediated current
was reduced in the oocytes expressing GAT1 when 10ng
cRNA for δOR were coinjected (Figure 4(b)) to a similar
extent as the GABA uptake (compared with Figure 3(b)).
As found for the uptake, activation of δOR by application
of DPDPE (100nM) led to further inhibition of GAT1-
mediated current by about 50%. Because DPDPE could
induce a Ca2+-dependent current (see above), the eﬀect of
DPDPE on GAT1-mediated current was, therefore, deter-
mined in the presence of DPDPE as the diﬀerence of current
in the presence and absence of GABA.
Similar to the ﬁndings with the GABA uptake, coex-
pression of μOR had no signiﬁcant eﬀect on the GAT1-
mediated steady-state current (Figure 4(b)), and activation
of the receptor by 100nM DAMGO did not signiﬁcantly
inﬂuence the current (Figure 4(c)). Also activation of the
endogenous acetylcholine (ACh) receptor by 100μMA C h
did not aﬀect the GAT1-mediated current (data not shown).
3.4. Eﬀect of Opioid Receptor Coexpression on GAT1-Mediated
Transient Current. Figure 4(a) illustrates, particularly for
depolarizing potential steps, that in the absence of GABA
a slow transient current was apparent. The amount of the
corresponding charge movements Q associated with the
extracellularNa+ binding[19]wasdeterminedbyintegration
of the transient current signals remaining after subtracting
from the responses in the absence of GABA those in
the presence of GABA [20, 21]. The voltage-dependent
distribution of the charges Q(E) is shown in Figure 5(a) and
can be described by a Fermi equation:
Q(E) = Q−∞ +
Q+∞ −Q−∞
1+e−zf (E−E1/2)F/RT , (2)
where F, R,a n dT have their usual meanings, zf represents
the eﬀective valence that is moved during the Na+ binding
step, and E1/2 the midpoint potential. Neither zf nor E1/2
was aﬀected by coexpression and activation of δOR, only
the amount of moved charges became reduced (see Table 1).
From the ratio of total charge Qmax = Q+∞ − Q−∞
and the eﬀective valence zf, the number of functionally
expressed transporters N can be calculated, and the values
are listed in Table 1. The coexpression of δOR obviously led
to a reduction in the number of functioning transporters
by about 30% which can only partially account for the
reduction of GABA uptake (about 70%, see Figure 3(b))o r
of GAT1-mediated current (about 75%, see Figures 4(b) and
4(c)). Also the further inhibition of the current by DPDPE
application(about50%,seeFigure 4(c))canonlypartiallybe
attributed to a reduction in N which amounts to only 25%.
Analysis of the kinetics of the transient currents yields
rate constants k (Figure 5(b)) of the signals that were6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Eﬀects of opioid receptor coexpression on GAT1-mediated current. (a) Current traces in response to rectangular voltage pulses
before, during, and after application of 100μM GABA to oocytes with expressed GAT1. Eﬀe c t so nt h ev o l t a g ed e p e n d e n c eo fs t e a d y - s t a t e
GAT1-mediated currents in oocytes coexpressed with δOR or μOR (10ng cRNA coinjected) (b) and of their activation by 100nM DPDPE
or DAMGO, respectively (c). Data in (b) and (c) represent averages ± SEM of at least 6 oocytes.
Table 1: Parameters of (1) ﬁtted to the data shown in Figure 5(a).
Qmax (nC) E1/2 (mV) zf Qmax/zf (N per oocyte) k
∗
1 (s−1) a1 (mV−1) k
∗
2 (s−1) a2 (mV−1)
GAT1 73.3
−32.3 1.2
6.1 × 1011 6.8
85.6
7.8
39.5 GAT1 + δOR 49.4 4.1 × 1011
3.3 5.4
GAT1 + δOR (1μM DPDPE) 39.7 3.3 × 1011
obtained by ﬁtting I = Imaxe−kt to the transient signal. The
voltage dependencies of the k values were ﬁtted by
k(V) = k1(V)+k2(V) = k∗
1 e−a1V +k∗
2 e
+a2V, (3)
where k1 and k2 represent the forward and backward
rate constants, respectively, of a step associated with the
extracellular Na+ binding (ﬁt parameters, see Table 1). All
datasets could be ﬁtted by the same voltage dependency;
the slowed kinetics on coexpression of δOR was dominated
by the reduced forward rate constant that could account
for reduced rate of GABA transport. Activation of δOR
by DPDPE did not aﬀect the kinetics. Neither the GAT1-
mediated steady-state currents nor the transient charge
movements were signiﬁcantly aﬀected when the rα2β Na+
pump was coexpressed with the GAT1.
Western blot analysis shows that coexpression of δOR
does not signiﬁcantly aﬀect the band intensity for GAT1
(Figure 6(a)). If any there may be a slight increase in band
intensity with coexpressed δOR of 7.4 ± 1.9% (Figure 6(b)).
Same loading of the lanes was conﬁrmed by same band
intensities for actin.Evidence-Based Complementary and Alternative Medicine 7
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Figure 5: Eﬀects of δOR coexpression and its activation by 100nM DPDPE on GAT1-mediated transient charge movements. 40ng of GAT1
cRNA alone or 40ng of GAT1 and 20ng of δOR cRNA were injected into oocytes. (a) Voltage dependencies of moved charge in response to
rectangular potential jumps were obtained by integration of the respective transient currents and were ﬁtted by (2) (see lines). (b) The rate
constants were obtained by ﬁtting an exponential to the transient current signal, and the voltage dependencies were ﬁtted by (3) (see lines).
Data represent means ± SEM; n = 6-7 oocytes for each group.
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Figure 6: GAT1 expression in Xenopus oocyte membrane fractions. (a) Lane 1: noninjected oocytes, lane 2: oocytes injected with 40ng of
GAT1cRNAand20ngofδOR,andlane3:oocytesinjectedwith40ngofGAT1cRNAalone.Thebandsatabout60kDa(seearrow)represent
GAT1 monomers. (b) GAT1 monomer band intensities averaged from 5 batches of oocytes and normalized to the respective batch injected
with cRNA for GAT1 only.
3.5. Activation of δ-Opioid Receptor Inhibits GAT1-Mediated
Current in PAG Neurons. The above data have demonstrated
that δOR interferes with GAT1 activity; in particular, acti-
vation of the opioid receptor inhibits GAT1 function. Since
these eﬀects might be a result of overexpression in the oocyte
model system, we investigated the eﬀect of δOR activation in
brain slices of rat PAG.
Steady-state currents were determined during superfu-
sion of the brain slice with diﬀerent solutions; in a typical
experiment sequence was
SGABA −→ SGABA+inhibitor −→ SGABA (4)
with SGABA representing solution with GABA and
SGABA+inhibitor solution with additional GAT1-speciﬁc
inhibitor tiagabine or NNC711. To determine GAT1-
mediated current, the currents in SGABA before and after
application of the inhibitor were averaged, and the current
in the presence of the inhibitor was subtracted to obtain
the current component sensitive to the speciﬁc inhibitor.
Thereafter, solutions in the presence of the δOR against
DPDPE were applied:
SGABA −→ SGABA+inhibitor. (5)8 Evidence-Based Complementary and Alternative Medicine
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Figure 7: Eﬀect of δOR activation on GAT1-mediated current in rat brain slices from PAG area. Whole-cell patch-clamp recordings were
performed on PAG neurons superfusing with diﬀerent solutions. (a) Steady-state current voltage dependencies of a single experiment with
solution sequence as given in the text. The inset shows the GAT1-mediated current determined as tiagabine-sensitive steady-state current.
Open squares represent current in the absence and ﬁlled squares in the presence of 100nM DPDPE. (b) GAT1-mediated current from 5
experiments. Data were normalized to the current at −100mV in the absence of DPDPE and represent averages (±SEM). The value of “one”
corresponds to 41.4 ±20.0pA.
Correspondingly, the GAT1-mediated current was deter-
mined as the diﬀerence of current in the absence and pres-
ence of the GAT1 inhibitor. Figure 7(a) shows an example.
For the GAT1-mediated current averaged data are presented
in Figure 7(b).
The result revealed strong inhibition of GAT1-mediated
currentinresponsetoapplicationoftheδOR-speciﬁcagonist
DPDPE (Figure 7). The nearly complete inhibition of total
GAT1-mediated current indicates that in the brain slices all
transportmodesofGAT1wereblocked.Hence,thesedataon
PAGslicesareconsistentwiththeDPDPE-inducedreduction
of GAT1-mediated GABA uptake and current observed in
oocytes.
4. Discussion
The discovery that the opioid receptor antagonist naloxone
counteracts acupuncture-induced analgesia [47, 48]l e dt o
the suggestion of the involvement of endorphins. Adminis-
tration of opiates to rats resulted in reduced GABA uptake
in brain as determined from measurements in synaptosomes
(Figure 1). The GABAergic system also plays a critical role
in pain sensation, and in particular inhibition of GAT
in mice has antinociceptive eﬀects and transgenic GAT1-
overexpressingmicearehyperanalgesic[11].SincetheGABA
concentration is controlled to a large extent by the GABA
uptake transporter, we investigated eﬀects of opioid receptor
expression on GAT1 function. To avoid interference with
other GABAergic components, we used the Xenopus oocytes
as an expression system. This was also useful since the
oocytes do not express endogenous functional Na+ channels
that have been demonstrated to be also regulated by δOR
[49].
4.1. Coexpression of δOR Reduces Transport Mediated by
GAT1. Coexpression of the δOR with GAT1 from mouse
brain led to downregulation of GABA uptake in the oocytes
with half maximum inhibition at about 10ng of cRNA
of δOR (Figure 2); this means at a cRNAδOR/cRNAGAT1
ratio of 0.25. The GAT1-mediated current was also reduced
(Figure 4(b)). The eﬀects of δOR coexpression on GABA
transport cannot be attributed to competition by the coin-
jected cRNAs. Neither the translation machinery nor the
targeting to the surface membrane was a limiting factor.
This became apparent from the observation that GABA
uptake was hardly aﬀected by coexpression of another
membrane protein (Na+ pump), and Na+-pump expression
was not aﬀected by δOR expression (Figure 2). The reduced
transport without activation of δOR cannot be attributed
to a background activity of the receptor since application
of the opioid-receptor antagonist naloxone did not have a
compensating counteractive eﬀect.Onlya slightlystimulated
uptake could be detected in the presence of 100nM naloxone
(Figure 3(a)). δOR seems to directly interfere with the
GAT1 leading to the reduced GABA uptake. This eﬀect
was speciﬁc for δOR since coexpression of μOR did aﬀect
neither GAT1-mediated GABA uptake (Figure 3(b))n o r
current (Figure 4(b)); also transport activities of EAAC1 and
the Na, K pump were not aﬀected [9, 50, 51]. Interaction
of membrane receptors with transport systems withoutEvidence-Based Complementary and Alternative Medicine 9
activation of the receptor was also reported previously.
The glutamate transporter EAAC1 as well as the Na, K
pump showed reduced transporter activity with coexpressed
δOR [9, 50, 51], and for the dopamine transporter DAT
reduced [52]a sw e l la si n c r e a s e d[ 53] uptake was reported
for coexpression with G-protein receptors. This eﬀect was
speciﬁc for δOR since coexpression of μOR did aﬀect neither
GAT1-mediated GABA uptake (Figure 3(b))n o rc u r r e n t
(Figure 4(b)); also transport activities of EAAC1 and the Na,
Kp u m pw e r en o ta ﬀected [9, 50, 51].
The speciﬁcity of the eﬀect of coexpression of δOR
on the GABA transporter becomes also apparent from the
observation that targeting of the rat α2β Na+,K + pumps
to the surface membrane of the oocyte was not aﬀected by
coexpression of δOR (Figure 2). In addition, coexpression
of the rat Na+,K + pump neither reduced GABA uptake nor
GAT1-mediatedcurrent,andthenumberoftransporterswas
not signiﬁcantly aﬀected either (data not shown).
Western blot analysis also demonstrated that coexpres-
sion of δOR did not aﬀect the amount of GAT1 expressed
in the oocytes and targeted to the membrane. Nevertheless,
the number of functioning transporters calculated from the
Qmax value became reduced by about 30% (see Table 1)o n
coexpression of δOR. “Functioning transporter” means that
at least Na+ can still bind giving rise to the transient current
signal, but it does not necessarily mean that GABA can be
transported. The inhibition of transport, therefore, might
be attributed to a reduced number of GABA-translocating
GAT1 molecules in the membrane and to a reduced rate
of transport. The reduced apparent aﬃnity for extracellular
Na+ binding (reduced rate of binding and increased rate of
unbinding (Figure 5(b)) supports the view of a contribution
of a reduced turnover rate of the transport cycle.
4.2. Activation of δOR Reduces Transport Mediated by GAT1.
As a supraspinal locus for opioid analgesia PAG exhibits high
abundance of δOR (see, e.g., [54, 55]) and also expression
of GAT1 has been demonstrated [56]. In Xenopus oocytes
with coexpressed δOR and GAT1 activation of δOR by
DPDPE led to further reduction of GAT1-mediated current
(Figure 4(c)) compatible with the ﬁnding of reduced GABA
uptake activity (Figure 3(b)). Compared to nonstimulated
δOR,theinhibitionofcurrentamountsto41%andofuptake
to 45%.
Redistribution of transporters between cytoplasmic
membranes and the surface membrane resulting in altered
transport had been attributed to activity of protein kinase
C( P K C )[ 57]. Opioid receptor activation with activation of
PKChadindeedbeenobservedpreviously[58,59].Hencewe
may speculate that the inhibition of GAT1 activity by δOR
activation might be regulated by PKC; an altered GAT1-δOR
interaction might also be considered as had been suggested
for the stimulation of glutamate uptake on activation of δOR
[9]. This of course needs further investigations.
AlteredGABAtransportasaconsequenceofactivationof
G-protein-coupled receptor has been discussed on the basis
of indirect eﬀects through altered Na+ gradient [60]. Such
a mechanism can be excluded for the oocytes since intra-
cellular Na+ activity hardly changes during an experiment,
and more direct eﬀects (see, e.g., [61]) have to be considered
including the action of protein kinases and phosphatases.
Stimulation of PKC alters GABA uptake by redistribution
of the transporters between intracellular compartments and
the surface membrane [57, 62], but also reduced activity
of the GABA transporter has been observed (Eckstein-
Ludwig and Schwarz (unpublished)). Mechanisms have been
discussed that protein-protein interaction like interaction
with syntaxin A or other adaptor proteins modulates the
GABA transporter [63] that may be modulated by PKC
[64]. Also other transport proteins, channels, G-protein-
coupled receptors, and cytoplasmic proteins [65–68]s e e mt o
be aﬀected by protein-protein interactions.
The inhibition of GAT1-mediated current cannot be
attributed to an overexpression of GAT1 and/or δOR in
the model system “Xenopus oocyte.” This we demonstrated
by patch-clamp experiments on PAG brain slices (Figure 7);
application of the δOR-speciﬁc agonist DPDPE resulted in
nearly complete inhibition of tiagabine-sensitive current that
can be considered to be mediated by GAT1. In Xenopus
oocyte activation of δOR did not completely inhibit the
GAT1-mediated current as well as uptake. This may be due
to the ratio of injected cRNA for GAT1 and δOR; we found
(not shown) that the degree of uptake inhibition by δOR
activationincreaseswithloweramountsofinjectedcRNAfor
δOR.
The signaling pathway in the oocytes deﬁnitively diﬀers
from that in the brain and might be the reason for the
diﬀerentlypronouncedeﬀectsontheGAT1transportmodes.
Our results suggest that stimulation of δOR can modulate
the GAT1 activity. Interestingly, while δOR activation leads
to inhibition of GAT1-mediated current, the glutamate
transporter EAAC1 becomes stimulated [9]. In addition to
this modulation of synaptic transmission, modulation of
neurotransmitter release by stimulation of opioid receptors
has been reported [69, 70].
In the presented work we have demonstrated that GAT1-
mediated transport can be regulated by the G-protein-
coupled δ-opioid receptor in two ways: (1) by modulation of
the number of functional transporters in the membrane and
(2) by modulation of transport activity. These modulations
are dominated by the presence of δOR and by receptor acti-
vationsuggestingthatdirecttransporter-receptorinteraction
plays the dominating role. Chronic morphine treatment
is known to modulate the surface expression of δOR.
For example, it blocks agonist-induced δOR internalization
[71]. The dynamics of δOR surface expression will thus
regulate GABA transporter activity. Since reduced GABA
reuptake will lead to elevated GABA concentration in the
synaptic cleft, this mechanism may account for the increased
GABAergic activity found in chronic opiate-treated rats and
its role in pain sensation.
5. Conclusion
It has been show previously that Na+ channel inhibition by
δOR activation may contribute to attenuation of disrup-
ture of ionic homeostasis present under hypoxic/ischemic10 Evidence-Based Complementary and Alternative Medicine
conditions [72]. Activation of δOR can stimulate the neu-
rotransmitter transporters EAAC1 [9] and inhibit the neu-
rotransmitter transporter GAT1 (this work). Stimulation of
EAAC1 will lead to reduced concentration of the excitatory
neurotransmitter glutamate in the synaptic cleft and inhi-
bition of GAT1 to elevated concentration of the inhibitory
transmitter GABA. We like to suggest that the acupuncture-
induced elevation of endorphins [24]c a nc o n t r i b u t et o
analgesia by regulation of the dominating excitatory and
inhibitory neurotransmitter transporters by activation of
δOR.
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